reports
National Healthcare Corp: 2 directors
Two Directors at National Healthcare Corp sold/gave away 3,454 shares at between 0.000USD and 139.420USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Confere...
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference. Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visitin...
Dorman Products Inc: 1 director
A director at Dorman Products Inc sold 2,000 shares at 128.798USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Axogen Announces FDA Approval of Biologics License Application for AVA...
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged ...
Middlefield Banc Corp. Announces 2025 Fourth-Quarter Cash Dividend Pay...
Middlefield Banc Corp. Announces 2025 Fourth-Quarter Cash Dividend Payment MIDDLEFIELD, Ohio, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share. The 2025 fourth-quarter dividend is payable on December 12, 2025, to shareholders of record on November 28, 2025. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.98 billion at September 30, 202...
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Jefferies Global Healthcare Conference (London)Participation: Fireside chat and 1x1 investor meetingsDate/Time: Fireside Chat Tuesday, November 18, 2025, 4:30 PM GMTWebcast Link: Canaccord Genuity MedTech...
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Axogen, Inc. Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a ...
Dorman Products, Inc. Reports Third Quarter 2025 Results
Dorman Products, Inc. Reports Third Quarter 2025 Results Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $543.7 million for the quarter, up 7.9% compared to $503.8 millionDiluted earnings per share (“EPS”) of $2.48, up 38% compared to $1.80Adjusted diluted EPS* of $2.62, up 34% compared to $1.96Reaffirms its full-year guidance for 2025 COLMAR, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM), a leading supplier in the motor vehicle aftermarket industry, today announced its financial res...
Middlefield Banc Corp. Reports 2025 Nine-Month Financial Results
Middlefield Banc Corp. Reports 2025 Nine-Month Financial Results MIDDLEFIELD, Ohio, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today reported financial results for the nine months ended September 30, 2025. 2025 Third-Quarter Financial Highlights (on a year-over-year basis): ●Third quarter diluted earnings increased to $0.65 per share, driving year-to-date earnings of $2.01 per share ●Pre-tax, pre-provision earnings(1) increased 37.3% to $6.8 million ●Net interest margin expanded 33 basis points to 3.79% ●Total loans increased $102.5 million, or 6.8% to a re...
Dorman’s Complex Electronic Solutions Portfolio Expands With OE FIX® E...
Dorman’s Complex Electronic Solutions Portfolio Expands With OE FIX® EPS Rack for Ram Trucks COLMAR, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (NASDAQ:DORM) has released the aftermarket’s first-ever, all-new electronic power steering (EPS) rack engineered to fit more than two million Ram pickup trucks. The EPS rack is the culmination of a multi-year research, development, and commercialization effort executed by a cross-functional team across the enterprise. “Dorman’s unique capabilities allow us to design, engineer, test, and bring to market highly complex assemblies,...
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October...
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the con...
Dorman Products, Inc. Announces Date to Report Third Quarter 2025 Fina...
Dorman Products, Inc. Announces Date to Report Third Quarter 2025 Financial Results COLMAR, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM) today announced the Company will report its financial results for the third quarter ended September 27, 2025, after the closing of the Nasdaq Stock Market on October 27, 2025. The Company also announced that it is scheduled to conduct a conference call and webcast to discuss its third quarter 2025 financial results on October 28, 2025, at 8:00 a.m. ET. The conference call can be accessed by dial...
Middlefield Banc Corp. Appoints Tim Oyster VP, Western Ohio Commercial...
Middlefield Banc Corp. Appoints Tim Oyster VP, Western Ohio Commercial Relationship Manager MIDDLEFIELD, Ohio, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that Tim Oyster has been appointed VP, Western Ohio Commercial Relationship Manager. In this role, Oyster will focus on delivering strategic advice to business clients in the Western Ohio Region, helping them improve cash flow, finance key assets, and mitigate risk. Mike Cheravitch, Chief Banking Officer, stated, “As we expand our commercial banking operations, Tim offers the expertise, lea...
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences: Cantor Global Healthcare Conference (NYC)Participation: Fireside chat and 1x1 investor meetings Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ETWebcast Link: Wells Fargo Healthcare Confere...
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft FDA PDUFA goal date extended by three months ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FD...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Middlefield Banc Corp. Announces 2025 Third-Quarter Cash Dividend Paym...
Middlefield Banc Corp. Announces 2025 Third-Quarter Cash Dividend Payment MIDDLEFIELD, Ohio, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share. The 2025 third-quarter dividend is payable on September 12, 2025, to shareholders of record on August 29, 2025. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.92 billion at June 30, 2025. The...
Axogen, Inc. Reports Second Quarter 2025 Financial Results
Axogen, Inc. Reports Second Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 17% Growth or $219 Million ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024,...
Dorman Products, Inc. Reports Second Quarter 2025 Results and Raises F...
Dorman Products, Inc. Reports Second Quarter 2025 Results and Raises Full Year 2025 Guidance Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $541.0 million for the quarter, up 7.6% compared to $503.0 millionDiluted earnings per share (“EPS”) of $1.91, up 25% compared to $1.53Adjusted diluted EPS* of $2.06, up 23% compared to $1.67Raises its full year guidance for 2025 COLMAR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM), a leading supplier in the motor vehicle aftermarket industry, ...
Middlefield Banc Corp. Announces Additions to Banking Team
Middlefield Banc Corp. Announces Additions to Banking Team John Cunningham appointed Northeast Ohio Commercial Market ExecutiveThomas Young appointed Northeast Ohio Commercial Relationship ManagerNick Paradiso appointed Central Ohio Commercial Relationship ManagerMiddlefield also announces the retirement of Jack Gregorin Northeast Ohio Commercial Relationship Manager MIDDLEFIELD, Ohio, July 31, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that John Cunningham has been appointed Northeast Ohio Commercial Market Executive, Thomas Young has been appointed N...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.